Posts Tagged ‘GLP-1 agonists’

One of the harms that weight stigma causes is the avoidance of medical care. But an unexpected side effect of GLP-1 therapy in persons with overweight or obesity may be increased engagement with healthcare. This insight comes from a new analysis of electronic health records for 711,783 persons. As the use of these medicines for […]

Let’s be quite clear. This is encouraging news, but it is nothing more than a glimmer of a possibility that there is a drop in U.S. obesity prevalence showing up in 2023. The data come from electronic health records. From a sample of 16,743,822 U.S. adults, Benjamin Rader, Rebecca Hazan, and John Brownstein analyzed 47,939,382 […]

 Why can’t they just go away? When compounded GLP-1 medicines started showing up two years ago, they seemed like a temporary distraction. In The New Yorker, Jia Tolentino described a dubious concoction of semaglutide she obtained from a compounding pharmacy for herself to mix and inject. “No thanks,” we wrote, hoping this sketchy business would […]

Yesterday, Amgen released topline data on their remarkable monthly obesity medicine – MariTide or maridebart cafraglutide. To us, the results are impressive, albeit preliminary. In 52 weeks of study, patients with obesity or overweight lost approximately 20% of their initial body weight and even after a year, they appeared to still be losing weight. For […]

For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]

A new study presented at the Annual Scientific Sessions of the American College of Gastroenterology tells us receiving a GLP-1 for diabetes with or without obesity is associated with a halving of pancreatic cancer risk. Is this too good to be true? Observational, of Course The first thing to note is that the finding comes […]

With detailed reporting in New York Times Magazine, Tomas Weber suggests that GLP-1 medicines “turn consumers off ultra-processed foods” and threaten to “crush the junk-food business.” He has woven a great collection of anecdotes into an appealing narrative. For instance, Kathleen Kenney has lost more than 100 pounds on these advanced medicines. She tells a […]

As we travel to San Antonio for ObesityWeek 2024 (OW2024) one of the principal threads we want to explore is the expanding scope of GLP-1 therapy benefits. The narrative is a moving target. We won’t have the abstracts in hand for another day. But news this week makes it clear that we have barely gotten […]

“Our results provide a national contemporaneous estimate of the decline in metabolic bariatric surgery associated with the era of GLP-1 RAs.” Writing in JAMA Network Open last week, Kevin Lin, Ateev Mehrotra, and Thomas Tsai say rates of metabolic surgery dropped 26% in 2023 as use of GLP-1 medicines for obesity more than doubled. Nonetheless, […]

Adolescence is hard. With respect to mental health, especially of late, the environment is especially harsh. Even harsher if an adolescent is living with obesity. So a recent study in JAMA Pediatrics showing teens with obesity are having fewer suicidal thoughts when they get a GLP-1 is welcome news. Authors Liya Kerem and Joshua Stokar […]